Session Information
2008 Midyear Clinical Meeting
Click here to go to the previous page
Controversies in Dyslipidemia
Track:
Educational Sessions
Program Code: 241-L01
Date: Tuesday, December 9, 2008
Time: 2:00 PM to 5:00 PM EST
Location:
S230G
MEETING PLANNING ASSOCIATE:
Ms. Naomi Schultheis, MEd, Director, Standards Development and Training, American Society of Health-System Pharmacists
PRESENTER(S):
Click the plus sign to see more detailed information about each speaker.
Click the plus sign to see more detailed information about each speaker.
Kwadwo Amankwa, Pharm.D. Robert Talbert, Professor
LEARNER OUTCOMES:
- Based on interpretation of the results of the ENHANCE study, make recommendations for the use of ezetimibe alone and/or in combination with statins.
- Describe potential mechanisms of antihyperlipidemic drug-induced myopathies and recommend strategies for prevention and management of antihyperlipidemic drug-induced myopathies.
- Describe the evidence supporting the use of omega-3 fatty acids, soy protein and other CAM for managing dyslipidemias.
- Explain the known and potential benefits to decreasing triglycerides.
- Explain the potential clinical relevance of pleiotropic effects of statins and describe recent data on the risks vs benefits of raising HDL limits.